The use of a bioactive skin substitute decreases length of stay for pediatric burn patients

Jeffrey R. Lukish, Martin R. Eichelberger, Kurt D. Newman, Maryland Pao, Kerilyn Nobuhara, Maryam Keating, Naomi Golonka, Geraldine Pratsch, Vinita Misra, Eric Valladares, Patricia Johnson, James C. Gilbert, David M. Powell, Gary E. Hartman

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Background: To optimize burn care for children, the authors introduced a protocol incorporating the use of a bioactive skin substitute, TransCyte (Advanced Tissue Sciences, La Jolla, CA). This study was designed to determine whether this management plan was safe, efficacious, and decreased hospital inpatient length of stay (LOS) compared with conventional burn management in children. Methods: All pediatric burns greater than 7% total body surface area (TBSA) that occurred after October 1999 underwent wound closure with TransCyte (n = 20). These cases were compared with the previous 20 consecutive burn cases greater than 7% TBSA that received standard therapy. Standard therapy consisted of application of antimicrobial ointments and hydrodebridement. The following information was obtained: burn mechanism, age, size of burn, requirement of autograft, and LOS. Data were analyzed using the student's t test. Results: Data for age, percent TBSA burn and LOS are reported as means ± SEM. The children who received standard therapy were 2.99 ± 0.7 years compared with those receiving TransCyte were 3.1 ± 0.8 years. There was no difference between the treatment groups with regard to percent TBSA burn: standard therapy, 14.3 ± 1.4% TBSA versus TransCyte, 12.7 ≈ 1.3% TBSA. There was no difference in the type of burns in each group, the majority were liquid scald type, 70% in the standard therapy group versus 90% in the TransCyte group. Only 1 child in the TransCyte group required autografting (5%) compared with 7 children in the standard therapy group (35%). Children treated with TransCyte had a statistically 6 significant decreased LOS compared with those receiving standard therapy, 5.9 ± 0.9 days versus 13.8 ± 2.2 days, respectively (P =.002). Conclusions: This is the first study using TransCyte in children. The authors found that this protocol of burn care was safe, effective, and significantly reduced the LOS. This new approach to pediatric burn care is effective and improves the quality of care for children with burns.

Original languageEnglish (US)
Pages (from-to)1118-1121
Number of pages4
JournalJournal of pediatric surgery
Issue number8
StatePublished - 2001
Externally publishedYes


  • Bioactive skin substitute
  • Pediatric burns
  • TransCyte
  • Wound care

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'The use of a bioactive skin substitute decreases length of stay for pediatric burn patients'. Together they form a unique fingerprint.

Cite this